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Abstract.
BACKGROUND: Recent clinical studies have indicated the beneficial impact of dietary flavonoid intake on human cognitive
performance. Although the mechanisms that mediate such improvements are currently unclear, animal and human trial data
suggest that changes in neurotrophin expression, and related signalling apparatus, may be involved.
OBJECTIVE: To investigate the link between changes in serum brain-derived neurotrophic factor (BDNF) and changes in
human cognitive performance following flavonoid intake.
METHODS: The relationship between serum levels of BDNF and age, gender, BMI, waist circumference, blood pressure
and cognition at baseline, and following flavonoid intake, was investigated in two distinct randomised, controlled clinical
trials. Trial 1 was conducted in men and women (aged 26–70 y; consuming an average of 3 portions of fruit and vegetables
per day) and delivered high-flavonoid (>15 mg/100 g) or low-flavonoid (<5 mg/100 g) fruit and vegetables and increased
intake by 2 portions every 6 weeks. The control arm was habitual diet over the same time frame. Trial 2 was conducted in
an older males and female cohort (aged 62–75 y) intervening with a high-flavanol cocoa drink (494 mg total flavanols) and
a low-flavanol cocoa drink (23 mg total flavanols) for 12 weeks.
RESULTS: Serum BDNF levels increased linearly to the age of 65, after which BDNF levels were found to decrease
markedly. All other physiological and anthropometric measurements proved to not be significantly associated with serum
BDNF levels (p > 0.05), although higher levels in males compared to females almost achieved significance (p = 0.056). At
baseline, higher serum BDNF levels were associated with significantly better global cognition scores, relative to individuals
with lower serum levels. In addition, following intervention for 18 weeks, high-flavonoid, but not low-flavonoid, fruit and
vegetable intake induced significant improvements in cognitive performance and increases in serum BDNF levels (p = <0.001).
Flavanol intervention for 12 weeks also resulted in significant increases in serum BDNF (p = <0.001), and such increases
were correlated with improvements in global cognitive performance.
CONCLUSION: Increases in global cognition induced by high flavonoid fruit and vegetables, and cocoa flavanols were paral-
leled by concurrent changes in serum BDNF levels, suggesting a role for BDNF in flavonoid-induced cognitive improvements.
Furthermore, we provide further data suggesting that serum BDNF levels may represent a biomarker of cognitive function.
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1. Introduction
Intake of dietary flavonoids, particularly flavanols
and anthocyanins, has been reported to improve
endothelial (dependent and/ or non-dependent)
vasodilatation [1, 2], blood pressure [3], glucose
metabolism and insulin resistance [4], and more
recently cognitive function and task performance
[5]. Collectively, these health-promoting effects may
in part support the inverse association between
flavonoid intake and risk of chronic disease, includ-
ing vascular-related diseases and dementia [6–8].
Randomised, controlled dietary intervention trials
conducted in animal models and humans investigat-
ing flavonoid-rich foods, including Camellia sinensis
(tea) [9, 10], Vitis Vinifera (grape) [11–13], Ginkgo
biloba [14], Theobroma cacao (cocoa) [15–21], Vac-
cinium spp (blueberry) [22–24], have indicated such
diets may enhance memory and learning [12, 25],
although the mechanisms by which they promote
such activity is currently unclear.
Previous animal studies have suggested that
improvements in cognitive performance in response
to flavonoid intake may involve the induction of
brain derived-neutrophic factor (BDNF) gene expres-
sion and protein synthesis [26]. BDNF is identified
as a significant protein for optimal structure and
function of hippocampal synapses, supporting the
function of long-term memory in humans [27–29].
Previous research has shown that the use of pro-
tein synthesis inhibitors and inhibitors of BDNF
signalling can lead to impairment of long-term mem-
ory and once expressed in neurons of the central
nervous system (CNS) BDNF has various func-
tions, including enhancing the survival and activity
of a large number of non-neuronal cells [30, 31],
as well as critical roles in synaptic plasticity [32],
nerve cell growth [33] and neuronal regeneration
following nerve injury [34–37]. Changes in BDNF
expression have been postulated to influence the size
of brain regions, memory functioning and anxiety-
related behaviour [38]. Indeed, its growth factor-like
effects promote both neurogenesis and angiogenesis,
and it may also aid the recruitment of circulat-
ing cells to facilitate cellular regeneration after
ischemic injury [33]. In support of these hypotheses,
both targeted mutations in BDNF or BDNF knock-
out results in deficient memory and learning and
a significantly shorter lifespan [39]. Previous ani-
mal data suggest that anthocyanin intake enhances
spatial working memory and that such changes are
correlated with both increased hippocampal CREB
activity and BDNF levels [26]. In support of this,
in vitro studies suggest that physiologically relevant,
nanomolar levels of flavonoids, in particular flavanols
and flavanones, may activate the ERK pathway, lead-
ing to downstream CREB phosphorylation/activation
[40–44].
Interactions are suggested to exist between BDNF,
age-related cognitive decline and other cognitive-
behavioural disorders. Age-related hippocampal
atrophy is associated with memory-impairment, and
therefore it is hypothesised that lower BDNF lev-
els partly mediate this physiological change [45].
Additionally, decreased BDNF functionality has been
associated with clinical depression and may also con-
tribute to the pathogenesis of schizophrenia [46–48].
In addition to the brain, synthesis of BDNF also
occurs in other cell types, including endothelial
cells. An ex vivo study found that synthesis of
BDNF in vascular endothelial cells may contribute
to the circulating pool of BDNF in humans [49]
and undergoes activity-dependent release and may
be transported across the blood–brain barrier [50].
Despite the growing number of studies linking the
intake of flavonoid-rich foods to cognitive improve-
ments, little is known about the mechanisms of action
and whether peripheral factors may also mediate
such events in the brain. As such, we hypothesize
that the improvements in human cognitive function
induced by flavonoid intake are, in part, mediated by
increased expression of BDNF in both the brain and
periphery. Additionally, we investigate the potential
use of serum BDNF measurement as a biomarker
of cognitive performance in humans. To address
this, we have conducted a human RCT administer-
ing both high- and low-flavonoid interventions in
order to establish whether flavonoid intake influences
human cognition and whether such improvements are
linked to concurrent changes in serum BDNF lev-
els. Results of this trial aim to support the evidence
that suggests a causal relationship between flavonoid
intake and associated improvements in cognitive
function.
2. Materials and methods
2.1. Study design
During this study two clinical trials were per-
formed. Clinical trial 1: Two cohorts (totaling
154 individuals) of men and women aged 26–70 y
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were recruited to the FLAVURS trial according
to inclusion and exclusion criteria, as previously
reported [51, 52] Notably, individuals consuming
less than the UK population average of 4.4 por-
tions F&Vs/d and those assessed to score more
than 2 on a modified Framingham CVD risk assess-
ment [51, 53] were recruited and randomly assigned
to 1 of 3 dietary groups via use of a minimisa-
tion procedure matching for age, sex, BMI, red
wine and tea consumption, and smoking. Risk mark-
ers were scored as follows: BP [either systolic BP
(SBP) of 130–139 mm Hg (1 point) or ≥140 mm Hg
(2 points) or diastolic BP (DBP) ≥90 mm Hg
(2 points)]; serum total cholesterol [5.2–6.1 mmol/L
(1 point) or 6.2–7.2 mmol/L (2 points)]; HDL choles-
terol [in men: 1.0–1.1 (1 point) or <0.9 mmol/L
(2 points); in women: 1.2–1.3 mmol/L (1 point)
or <0.9–1.1 mmol/L (2 points)]; obesity/adiposity
[either waist circumference in women of 80–87 cm
(1 point) or >88 cm (2 points) and waist circum-
ference in men of 94–101 cm (1 point) or >102 cm
(2 points) or a BMI (in kg/m2) of 25–30 (1 point) or
>30 (2 points); BMI for Asian populations: 23–27.5
(1 point) or >27.5 (2 points)]; and smoking sta-
tus [> 10 cigarettes/d (2 points)]. Before baseline
measures, all groups were blinded to the interven-
tions after assignment;. In total, 307 individuals were
screened; after identification of CVD risk, 221 were
recruited into the study, 174 were randomly assigned
to 1 of the 3 intervention groups, and 154 completed
all study visits.
A randomized, controlled, dose-dependent, par-
allel designed trial with 2 sequentially increasing
dose-response dietary treatments consisting of high-
flavonoid fruit and vegetables (HF) or low-flavonoid
fruit and vegetables (LF), against a control group
where habitual diet is maintained (control). Incre-
mentally, 2, 4 and 6 portions of fruit and vegetable
intake delivered 3, 6 and 7 mg/d (low-flavonoid
intervention) and 49, 121 and 198 mg/d (high-
flavonoid intervention) total flavonoids, respectively.
The trial was registered as a randomized clinical
trial (ISRCTN47748735) and conducted according
to the guidelines laid down in the Declaration of
Helsinki. Ethical approval for the study was obtained
from the Local Research Ethics Committee of the
Isle of Wight, Portsmouth and South East Hamp-
shire (REC: 07/H0501/81), and the University of
Reading’s Research (REC: 07/22) Ethics Committee.
Informed consent was obtained before participation.
After screening and random assignment, participants
were invited to the university for a familiarization
visit to acquaint them with the clinical setting and
measurements that would be performed on study
visits. This was followed by a 2-wk run-in period,
during which volunteers were asked to maintain their
current habitual diet and lifestyle. Following run-
in, participants attended a baseline visit (week 0),
where they were randomized onto either the HF, LF
or control intervention. The target intake of F&Vs
was increased over and above habitual intake by 2,
4, and 6 (+2, +4, and +6) 80 g portions/d over 3 con-
secutive 6-wk periods. Participants attended 4 study
visits at the Hugh Sinclair Unit of Human Nutri-
tion (weeks 0, 6, 12, and 18), where measures of
cognitive function were assessed and blood samples
were collected for BDNF analysis. Throughout the
study, participants were asked to maintain a con-
stant weight, minimize other health and lifestyle
changes, and to immediately report changes in medi-
cation status or other factors that may influence CVD
risk profile.
At the baseline visit (week 0), participants were
provided with information on the diet to which they
had been assigned, and close contact with the study
dietitian/nutritionist was maintained during the 18-
week period to provide dietary advice, motivation
and support. Portions of F&Vs were defined as 80 g
for fresh, frozen, or canned items, or 40 g for dried
items and ≥150 mL fresh juice. With the use of the
USDA flavonoids database [54], HF and LF foods
were defined as >15 mg/100 g and as <5 mg/100 g of
total flavonoids, respectively, with adjustments made
to account for fresh, dry, or canned F&V weight. All
F&Vs were provided to participants, and consider-
able effort was devoted to matching the intake of
other potentially bioactive components of the F&Vs
such as carotenoids, vitamin C, folate, and non-starch
polysaccharides. A variety of food sources were pro-
vided, including fresh, canned, frozen, and dried
F&Vs and juices and composite foods such as fruit
smoothies and pasta sauces. To aid compliance, all
F&Vs were provided to those in the LF and HF groups
and delivered to participants’ homes on a weekly
basis. Full details of the dietary intervention have
been reported previously [51].
2.2. Clinical trial 2
40 healthy volunteers (18 women and 22 men;
mean +/– SD age: 68.3 +/– 3 y) were recruited
from the University of Reading and surrounding
area. All volunteers were assessed as ‘healthy’ based
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on absence of medical treatment and/or supervi-
sion, response to a standard medical questionnaire,
a ‘Brief Symptom Inventory’ (a screening tool
for underlying depression), blood pressure mea-
surements and blood parameters (i.e. normal liver
enzymes, hemoglobin, hematocrit and leukocyte
counts). Volunteers were selected according to the
following inclusion/exclusion criteria: Inclusion cri-
teria: Aged 62–75 years, absence of food allergies
or sensitivity to chocolate, dairy, nuts or gluten; con-
sumers of less than 15 units (120 g) of alcohol per
week, native English speaker, MMSE ≥25. Exclusion
criteria: those under medical supervision and medical
treatment, including prescribed blood pressure medi-
cation, anti-depressants, anticoagulants, and sufferers
of chronic fatigue syndrome, liver disease, diabetes
mellitus, myocardial infarction and gall bladder or
gastrointestinal abnormalities. Those with hyper-
tension (systolic blood pressure above 160 mm Hg
and/or a diastolic blood pressure above 90 mm
Hg), anemia (hemoglobin >11.5), alcohol abuse
(gamma GT <80 IU/l), hearing impairments and color
blindness were also excluded. Those selected for the
study were asked to refrain from the consumption of
the following foods for 24 h prior to the study (includ-
ing the washout period): consumption of flavanol-rich
foods, including cocoa, chocolate, apples, and red
wine. They were also requested to refrain from par-
ticipating in vigorous exercise (>3 × 20 min/week)
and consuming caffeine and were requested to arrive
at each study appointment fasted, having only con-
sumed low-nitrate mineral water..
The study was conducted according to the
guidelines of the Declaration of Helsinki, and all pro-
cedures involving human subjects were approved by
the University of Reading Research Ethics commit-
tee (ref: 08/49). The study was also registered with
the National Institutes of Health (NIH)-randomised
trial records held on the NIH ClinicalTrials.gov web-
site (NCT01344551). The study was designed as
a randomised, controlled, double-masked, cross over
dietary intervention, in the course of which volun-
teers were asked to consume either a high-flavanol
cocoa drink (494 mg total flavanols) or a low-flavanol
cocoa drink (23 mg total flavanols) for 28 days. Inter-
vention drinks were provided by Mars Incorporated
(Hackettstown, NJ, USA) as dry, dairy-based cocoa
beverage mixes. All cocoa drinks were standardized
for their total cocoa flavanol content and profile,
and closely matched for macro- and micro-nutrient
content, caloric load, theobromine (HCF: 185 mg;
LCF: 177 mg) and caffeine content (HCF: 15 mg;
LCF: 17 mg) levels. All cocoa drinks were similar
in taste and appearance and were supplied in individ-
ual sachets labeled with an anonymous three-digit
code. The amount of total cocoa flavanols referenced
here is defined as the sum of all monomeric flavanols
and their oligomeric derivatives (dimers to decamers,
i.e. 2–10 monomeric subunits). Each treatment was
reconstituted in 200 mL of warm, nitrate/nitrite
free water and stirred until well mixed. Volun-
teers were asked to consume drinks immediately on
preparation.
All subjects and researchers involved in the
conduction of the study and assessment of study
outcomes were masked with regard to the nature
of the test materials consumed. An independent
researcher generated a random allocation sequence
(using restricted randomization), and allocated par-
ticipants into their groups. After the first intervention
period, there was a 4-week wash out period prior
to switching volunteers to the alternate arm of the
study. Following an overnight fast, volunteers con-
sumed a low-flavonoid breakfast (toast (200 g), butter
7 g), honey (10 g)), subjects were asked to com-
plete a cognitive test battery (2 sets of 40 minutes
with a 10 minute break). Following this, they were
asked to consume one cocoa beverage (one cocoa
sachet in ∼150 mL of water) every day after break-
fast for 28 days before attending the unit to undertake
a second round of cognitive testing (2 sets of 40
minutes with a 10 minute break), with individual
cognitive tests administered in the same order. Sub-
jects were advised not to alter their usual calorie
intake, were asked to document any unusual symp-
toms or side effects and to keep a diary of illness and
medication.
2.3. Cognitive function
Trained, blinded, research assistants administered
the neuropsychological test battery, which included
the primary measures of executive function and
episodic memory and secondary measures of working
memory, spatial memory, implicit memory, attention
and information processing and psychomotor speed.
The battery took approximately 1.5 hours to admin-
ister and on each visit a different, randomly assigned,
version of each task was administered. Global ‘Exec-
utive function’ was assessed using the following
tasks, which were combined to provide a compos-
ite score: (1) The inhibitory component of executive
function by Go-NoGo task [55–57] and Stroop [58,
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59] (2) The ‘shifting’ component of executive func-
tion by the plus-minus [60] and trail making tasks
[61–64] and (3) the updating component of execu-
tive function by letter memory task [65, 66], whilst
episodic memory was assessed by free and delayed
recall [67–69], word recognition and face recognition
[67]. Other cognitive domains assessed were work-
ing memory: assessed by serial sevens task [70–73];
spatial memory assessed by spatial delayed recall
task (SDRT) [74]; spatial memory using a virtual
3D radial arm maze task; implicit memory by the
word stem completion task [75]; and attention and
processing speed by the digital symbol substitution
task (DSST) [76–78] and rapid visual information
processing (RVIP) task [79].
2.4. BDNF measurement
Serum BDNF was assessed using a commercially
available, mature BNDF rapid ELISA kit (Biosensis,
mature BDNF; human, rat, mouse). It is generally
considered better to measure circulating BDNF in the
serum as its concentration in serum is about 100 folds
higher than plasma levels [80] and its concentration
in plasma is affected by blood handling due to the
degranulation of platelets [81, 82]. After collection
of whole blood, serum was separated by centrifu-
gation at 1800 × g for 10 minutes at 4◦C, aliquoted
and stored at –80◦C until use. Serum levels of BDNF
were quantified at baseline and following the intake of
increasing amounts of fruit and vegetables, or high-
and low-flavanol intake. Flat-bottom 96-well plates
were coated with anti-BDNF monoclonal antibody
(mAb; 1 : 1000) and left overnight. Following this,
plates were washed with TBST (20 mM Tris-HCl
(pH 7.6), 150 mM NaCl and 0.05% (v/v) Tween®
20), and blocked using a commercial block buffer
and incubated for 1 hour. Following an additional
wash step, defrosted serum samples were diluted
1 : 4 and added to wells (100l) and incubated for
2 h, before being washed with TBST. A second, spe-
cific BDNF polyclonal antibody (pAb) (anti-human
BDNF pAb; 1 : 500 dilution) was then added to wells
and incubated for 2 h. Plates were then washed bound
BDNF pAb was detected using a species-specific
anti-IgY antibody conjugated to horseradish per-
oxidase (HRP). Follwoing 1 h incubation, unbound
conjugate was removed by washing and 100 ml of
TMB (tetramethyl benzidine) was added to each well
and after a 10 min incubation the reaction was stopped
with 100 ml of 1 N HCl. Colour change was measured
at 450 nm within 30 min using Tecan GENios mul-
tiplate reader (Tecan GENios, Theale, U.K). The
BDNF concentration was calculated using a standard
curves constructed using authentic BDNF protein
(0–500 pg/ml).
2.5. Statistical analysis
All statistical analyses of data occurred in advance
of the authors being un-blinded and analysis was car-
ried out on the basis of intention-to-treat. Prior to
analysis, normality checks were performed on all
data and log transformations were carried out. All
statistical analysis was performed with Prism 5.0f
(GraphPad, San Diego, CA). Based on a medium
effect size (d = 0.65) in our preliminary work, using
young adults and the GoNogo task, we calculated
that a sample size of 60 participants would pro-
vide considerable power (0.97) to detect a similar
sized effect in older adults (p = 0.05). For consis-
tency, interpretability and in agreement with other
studies [83, 84] all cognitive test data were pooled
to calculate overall means and SD’s per test and
then converted to ‘Z’ scores. For the majority of
tests a higher score represented a better cognitive
performance so those where a higher score repre-
sented a poorer performance (GoNogo and Stroop
response times, Trails, Plus Minus, Vr Radial Maze)
those scores were multiplied by –1. In agreement with
another studies [83], data for the executive function
and episodic memory tasks were used to create a set
of z scores that were grouped for analysis into the
two separate domains of cognitive function: execu-
tive function = (Z Letter memory + Z Gonogo + Z Stroop +
Z Trails + Z Plus Minus)/5 and episodic memory = (Z
Free recall + Z Delayed recall + Z Word recognition + Z
Face recognition)/4. All effects were reported as signifi-
cant if P < 0.05. To determine differences in baseline
test performance between arms, a paired t-test was
used. Significant differences in the primary variables
of executive function and episodic memory and all
anthropometric and biochemical variables were cal-
culated by a 2 factor repeated measures ANOVA with
treatment and time as the two factors. Pearson cor-
relation analysis was performed to correlate BDNF
values with age, gender, BMI, WC and BP (SBP &
DBP) as well as z-score. Paired t-test used in order
to compare mean serum BDNF level in both male
and female subjects. When the BDNF data was split
into tertiles of age (35–50, 51–65 and 66–90), we
have used a one-way analysis of variance in order
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to indicate that the 3 means were significantly dif-
ferent from each other. Moreover Post hoc analysis,
using Bonferroni’s Multiple Comparison Test used to
compare BDNF levels in these three aged groups.
3. Results
3.1. Baseline correlation of serum BDNF
with anthropometric and cognitive markers
At baseline, correlation of BDNF values with
age (dividing volunteers in 2 age groups <65 and
>65 years old) indicated a significant positive corre-
lation at 5% level (95% confidence interval) between
the serum BDNF levels and age in volunteers aged
less than 65 years (P = <0.001; R2 = 0.203) (Fig. 1A).
In contrast, in those aged 65 years and above, a signif-
icant negative correlation was observed between the
two variables (p = <0.001; R2 = –0.5274) (Fig. 1B).
Moreover when the BDNF data was split into tertiles
of age (35–50, 51–65 and 66–90 years), a one-way
analysis of variance indicated that the 3 means were
significantly different from each other (p < 0.001)
(Fig. 1C). Post hoc analysis, using a Bonferroni mul-
tiple comparison test, indicated that the 51–65 group
had significantly higher BDNF levels compared to the
35–50 age group (P < 0.01), whilst the 66–90 group
had significantly lower BDNF levels than the 35–50
group (P < 0.05) and the 51–65 group (P < 0.001).
Mean serum BDNF levels were also found to be sig-
nificantly higher in males (214.1 pg/ml) compared
to females (246.4 pg/ml), albeit weakly (p = 0.046)
(Fig. 2A). No significant correlation between the
serum BDNF level and SBP (p > 0.05) and DBP
(p > 0.05) (Fig. 2B), or BMI (p > 0.05) (Fig. 3A)
and waist circumference (p > 0.05] (Fig. 3B) was
observed. At baseline, tertile analysis (serum BDNF:
<200 pg/ml; 200–300 pg/ml;>300 pg/ml) indicated
that as serum BDNF levels increased, there was
a significant increase in global cognitive perfor-
mance (<200 v > 300 pg/ml, p < 0.01; (200–300 v >
300 pg/ml, p < 0.05) (Fig. 4).
3.2. Inﬂuence of fruit and vegetable intake
on global cognition and serum BDNF
A two factor repeated measures ANOVA
(time × treatment) indicated that there was a signifi-
cant effect of time (p = 0.003), treatment (p = 0.069)
Fig. 1. Correlation between serum BDNF and age: (A) correlation
between BDNF and age for individuals up to 65 years; (B) BDNF
and age ages 65–90 years; C: Whisker Plot showing tertiles of
age against serum BDNF levels at baseline. A one-way analysis
of variance indicated that the 3 means were significantly different
from each other (P < 0.001). Post hoc analysis, using a Bonferroni
multiple comparison test, indicated that the 51–65 group had sig-
nificantly higher serum BDNF levels compared to the 35–50 age
group (a: p < 0.01), whilst the 66–90 group had significantly lower
BDNF levels than the 35–50 group (b: p < 0.05) and the 51–65
group (c: p < 0.001). Horizontal lines within bars indicates mean
level and bars indicates 25–75% distribution; Error lines indicate
the min and max serum BDNF levels measured.
and an interaction (p = 0.033) between dietary intake
and cognitive performance (Fig. 5A). Post hoc anal-
ysis, using a Bonferroni correction indicated that
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Fig. 2. Corellation of BDNF with anthopometric measures:
(A) Serum BDNF levels measured in males and females at base-
line. (B) Correlation of BDNF level with Systolic Blood Pressure
(SBP) and Diastolic Blood Pressure (DBP). Mean serum BDNF
levels showed a trend to be higher in males compared to females
(p = 0.056), whilst no significant differences between BDNF level
and either SBP (p > 0.05) or DBP (p > 0.05) were observed.
following HF F&V intake global cognitive perfor-
mance was significantly improved at 12 and 18 weeks
(p < 0.01), relative to both habitual diet (control) and
LF F&V intake (Fig. 5A). In parallel, a two fac-
tor repeated measures ANOVA indicated significant
time (p = 0.008), treatment (P < 0.005) and an inter-
action (p = 0.026) between serum BDNF and dietary
intake across the 12 weeks (Fig. 5B). Post hoc anal-
ysis indicated a significantly higher serum BDNF
level at 12 weeks in the HF F&V group, rela-
tive to the habitual diet (control) group (p < 0.001)
(Fig. 5B).
Fig. 3. Corellation of BDNF with bidy mass index (BMI; panel
A) and waist circumferance (WC; panel B). No signitivent corre-
lations were observed (p > 0.05; n = 112)
3.3. Inﬂuence of 12 week ﬂavanol intake
on cognition and serum BDNF
Intake of the high flavanol cocoa intervention for
12 weeks led to a significant increase serum BDNF
levels, relative to the low flavanol cocoa interven-
tion (Fig. 6A; p < 0.01) and global cognitive function
(Fig. 6B; p < 0.01). Plotted together, the data indicate
increases on both global cognition and serum BDNF
increase concurrently (Fig. 6B).
4. Discussion
Improvements in human cognitive function
brought about by the intake of dietary flavonoids
may be, in part, mediated by increased expres-
sion of BDNF in both the brain and periphery and
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Fig. 4. A) The relationship between Cognitive score (z-score) in
3 dietary groups over the period of 12 weeks. B) The relationship
between BDNF level and z-score (cognitive score) Each point rep-
resents a dietary group at a specific visit and is an average of their
z score and BDNF level for each. Hence there are 12 points.
additionally, such serum levels of this neurotrophin
may act as a potential biomarker of cognitive perfor-
mance in humans. We show that with the exception
of age, where there was a steady increase in serum
BDNF levels up to the age of 65, and a sharp
decline after 65 years, other anthropometric mea-
sures showed no correlation with serum BDNF levels.
This observation, broadly agrees with previous stud-
ies suggesting that the most significant changes in
BDNF occur in the elderly (∼70 years and above)
where cognitive decline is most marked [85, 86],
For example, [85] previous data indicate declines in
serum BDNF with age in a group of elderly subjects
aged between 70 and 103 years (r = –0.15), although
other studies have shown no significant age-related
changes in blood BDNF concentrations [50, 87] and
animal studies suggest that brain BDNF levels which
reflect serum BDNF concentrations [88] do not alter
with age [89, 90].
All other physiological and anthropometric mea-
surements proved to not be associated with serum
BDNF levels, although levels were slightly higher in
males compared to females. This fits with previous
observations [50, 86, 87, 91], although data concern-
ing the differences between males and females are
generally small and variable. We found no influence
Fig. 5. Influence of fruit and vegetable intake on cognition and
BDNF. (A) Time-course of changes in cognitive function follow-
ing consumption of high flavonoid F&Vs; low flavonoid F&Vs;
and after following habitual diet (Control). Data were analyzed
using two-way repeated measures ANOVA with time and treatment
as the two factors (significant effect of time (p = 0.003), treat-
ment (p = 0.069) and an interaction (p = 0.033) between dietary
intake and cognitive performance. Post hoc analysis, (Bonferroni)
indicated significantly greater cognitive performance at both 8
(∗∗∗p < 0.001) and 12 weeks (∗∗p < 0.01), relative to both habit-
ual diet (control) and LF F&V intake. (B) Impact of fruit and
vegetable intake on serum BDNF levels. A two way ANOVA with
repeated measures indicated significant time (p = 0.008), treatment
(P < 0.005) and an interaction (p = 0.026) between serum BDNF
and dietary intake across the 12 weeks. Post hoc analysis indi-
cated a significantly higher serum BDNF level at 12 weeks in
the HF F&V group, relative to the habitual diet (control) group
(∗∗p < 0.001). Details of the high and low classification of F&V
are outlined in the Materials and Methods section. All data are
plotted as mean values ± SEM (n = 112).
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Fig. 6. Influence of cocoa flavanol intake on cognition and serum
BDNF. (A) Intake of cocoa flavanols for 12 weeks led to a signifi-
cant increase serum BDNF levels, relative to the low flavanol cocoa
intervention (∗∗p < 0.01). (B) Impact of cocoa flavanol intake on
global cognition function, plotted with serum BDNF levels (Base-
line: ν = 40; 12 weeks). Cognitive performance was significantly
greater (∗∗p < 0.01) following high flavanol intake relative to the
low flavanol control. All data are plotted as mean values ± SEM
(n = 40).
of either BMI or waist circumference on BDNF
levels, which also agrees with previous data [50].
Furthermore, observations that there are no signif-
icant differences between serum BDNF in subjects
grouped as ‘underweight’ (<18.5 kg/m2), ‘normal’
(18.5–23.99 kg/m2) and ‘overweight’ (>24 kg/m2)
[86] similarly reflects our findings, although it
has been suggested that a positive correlation
between BMI and BDNF concentration may exist
in individuals that were obese or very underweight
[50, 92–94].
At baseline, there was a clear relationship between
the fasted serum BDNF level and cognitive perfor-
mance, which was most marked between the lowest
and highest serum BDNF groups. Previous analyses
of existing clinical studies have reported significantly
lower BDNF levels in patients with major depression
[95, 96], schizophrenia [96], bipolar disorders [97] or
autism spectrum disorders [98, 99]. Our data supports
a relationship between BDNF and z-score (global
cognitive score), suggesting that serum BDNF may
be able to predict cognitive performance and could
therefore present as a good biomarker for cognitive
activity. However, the use of serum BDNF levels as
a biomarker of global cognitive performance should
be considered with caution as a wide range of BDNF
levels in serum have been reported [87, 88, 101,
102] presumably reflecting the multitude of cellu-
lar sources of serum BDNF, including endothelial
cells and the brain [87], and its ability to readily
cross the blood–brain barrier in both directions [103,
104]. Moreover, studies have suggested that neu-
ronal BDNF synthesis and secretion is influenced
by several factors including exercise, stress and/or
active learning and memory [105–108]. Despite this,
we suggest that serum BDNF levels may represent
a rapid, crude indication of an individual’s global
cognitive performance, and therefore may present as
a useful biomarker of cognitive outcomes in future
research.
With regards to the diet-dependent changes in
BDNF levels, we found a significant impact of high-
flavonoid fruit and vegetable intake on serum BDNF
levels over an 18-week period but no changes follow-
ing low-flavonoid fruit and vegetable intake. It has
been previously suggested that a flavonoid-mediated
mechanism may impact on cognition, which in turn
may affect the expression of BDNF [26]. In sup-
port of this, the intake of cocoa flavanols in this
study also led to higher serum BDNF levels and
better cognitive performance following 12 weeks
of intake, relative to a well-matched, low flavanol
control. Whilst this suggests a correlative relation-
ship between BDNF levels and flavonoid-induced
improvements in cognition, it is presently difficult to
assign precise mechanisms, although it is assumed
that circulating flavonoid metabolites may induce
expression of BDNF, either within the brain, or in
the periphery, via activation of intracellular MAP
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kinase and PI3 kinase signalling pathways [5, 12, 25,
109]. As discussed earlier, animal data have indicated
that mutations within BDNF exons result in defi-
cient memory and learning [39], whilst anthocyanin
and flavanol intake has been shown to enhances spa-
tial working memory with concurrent increases in
both hippocampal CREB activity and BDNF levels
[26]. In vitro data suggest that such activity may pro-
ceed via flavonoid metabolite activation of the ERK
pathway, leading to downstream CREB phospho-
rylation/activation [40–44]. Alternatively, flavonoid
intake may induce BDNF expression in the periph-
ery, for example from the endothelium, where it may
influence vascular function [49, 110] or may cross
the blood brain barrier as influence neuronal and glial
cells directly.
In summary, the evidence from both trials suggests
that diet-induced changes in BDNF levels seemingly
reflect variations in cognitive performance in young
and old subjects following high-flavonoid interven-
tions. Thus, we suggest that changes in serum BDNF
levels may be, in part, related to the mechanism by
which flavonoids induce changes in global cognitive
function. Future directions of this work highlights the
potential to investigate the impact of age as a factor
determining the magnitude of change in cognitive in
response to flavonoid intake.
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